Abstract: The present invention provides a process for the preparation of a nonracemic a-amino acid derivative from an optically active N-acyl lactam using an organometallic reagent to effect the opening of the ring followed by reduction of the ketone carbonyl to an alcohol or a methylene, or by a reductive amination to an amine, or by a ketalization reaction.

Abstract: The invention relates to methods for preparing superporous hydrogels (SPH) that are very-pure and have desirable swelling properties necessary for commercial use, such as in food and pharmaceutical applications. Such methods include simultaneous use of low and high glass transition monomers to improve impurity and swelling profiles of the SPH, use of an integration means to prepare a very homogenous superporous hydrogel foam, washing the superporous hydrogel in a washing solution comprising different ratios of solvent to non-solvent (e.g., water/alcohol), use of a chemically-induced expansion/contraction process to enhance the efficiency of the multiple washing process and to fully structuralize the SPH, and employing one or more separation techniques, such as rubbing, filtration, centrifugation, compression and cutting to increase the efficiency of the purification process and to enhance the SPH swelling properties.

Abstract: Described is a method for treating and/or preventing disease states and conditions associated with defects in the activity of chloride channels, such as the CFTR channel. The present disclosure also described compounds useful in such treatment and prevention methods and methods for the identification of compounds for use in such methods. These compounds disclosed are NPPB, NPPB-Am, NPPB-sulf and curcumin, and derivatives of the foregoing. These compounds are shown to activate the activity of both wild-type and mutant CFTR channels under a range of conditions.

Abstract: Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.

Abstract: A method and system for performing motion estimation for a frame associated with a video signal. The method includes receiving at least a reference frame, a first frame, and a second frame, and providing a first plurality of vectors. The first plurality of vectors intersects the first frame within a first block and intersects the reference frame within a first plurality of blocks respectively. Additionally, the method includes determining a second plurality of vectors based on at least information associated with the first plurality of vectors. The second plurality of vectors intersects the second frame within a second block and intersecting the reference frame at a plurality of locations. Moreover, the method includes processing information associated with the plurality of locations, and determining a plurality of search areas corresponding to the plurality of locations in the second frame.

Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.

Abstract: A discharge-lamp control device for lighting a discharge-lamp includes two electrodes, first and second driving units to supply power to the discharge-lamp through the electrodes, respectively. Each driving unit includes a transformer having primary and secondary coils and a capacitor connected in parallel to the secondary coil. The first driving unit has impedance characteristics with a minimum impedance at a first frequency and a maximum impedance at a second frequency lower than the first frequency. The second driving unit has impedance characteristics having a minimum impedance at a third frequency and a maximum impedance at a fourth frequency lower than the third frequency. The first frequency is set to be higher than the third frequency. The second frequency is set to be lower than the fourth frequency. An operating frequency of the driving circuit is selected within a frequency bandwidth from the fourth frequency to the third frequency.

Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Abstract: Libraries of synthetic receptors are disclosed. The receptors include a polyfunctional organic template which is covalently linked to two or more oligomers. The oligomers may be the same or different and may be straight chain, cyclic or branched. The template may be linked to an identifier which is unique to each synthetic receptor. Although the identifier may be directly attached to the template, it is more common and preferable that the template be covalently linked to a solid support which is itself linked to the identifier. Methods of preparing synthetic receptors and libraries of synthetic receptors are also disclosed as are methods for assaying the libraries to determine which receptors have various desirable characteristics. Among the desirable characteristics are (a) the ability to bind an acceptor molecule; (b) biological activity; (c) the ability to catalyze or inhibit a reaction and (d) potential utility for separating compounds in chromatography.

Abstract: The present invention is directed to a discharge lamp drive device and a liquid crystal display device, capable of keeping a tube current balance among discharge lamps to thereby prolong life durations of the discharge lamps. A drive circuit 311 outputs an AC voltage. Ballast circuits 312, 322 include “n” pieces of ballast capacitors C11 through C1n and C21 through C2n, respectively. The ballast capacitors C11 through C1n and C21 through C2n have one ends commonly connected to one another and directed to drive circuits 311 respectively, and other ends individually connected to discharge lamp connection terminals, respectively. Connected in parallel to at least two of ballast capacitors C11, C21, and C1n, C2n, are tube current compensation capacitors Cb3 and Cb1 thereby increasing capacitances of the ballast capacitors, respectively.

Abstract: A discharge-lamp control device for lighting a discharge-lamp includes two electrodes, first and second driving units to supply power to the discharge-lamp through the electrodes, respectively. Each driving unit includes a transformer having primary and secondary coils and a capacitor connected in parallel to the secondary coil. The first driving unit has impedance characteristics with a minimum impedance at a first frequency and a maximum impedance at a second frequency lower than the first frequency. The second driving unit has impedance characteristics having a minimum impedance at a third frequency and a maximum impedance at a fourth frequency lower than the third frequency. The first frequency is set to be higher than the third frequency. The second frequency is set to be lower than the fourth frequency. An operating frequency of the driving circuit is selected within a frequency bandwidth from the fourth frequency to the third frequency.

Abstract: Disclosed are compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.

Abstract: Disclosed are compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H. receptor antagonist.

Abstract: A process for signal detection in EDGE cellular systems is presented with the step of wireless channel estimation, a time-reversed signal processor, a soft-output Viterbi signal detector consisting of forward and reverse block processing, a MAP decoder that exchange soft information with the equalizer. Claim 1. A signal detection mechanism to demodulate received data frame that includes an accurate estimator to obtain channel responses, a forward filter and a FIR decision feedback filter to be used in soft-output equalizer, a time-reversal device storing received data in a time-reversed order for reverse block processing, an interference removal apparatus in both forward and reverse processing blocks, and a soft-input soft-output reduced state equalizer that utilizes the forward processing and reversed time processing blocks to generate iterative soft-output signals to the forward error correction decoder within the receiver system.

Abstract: A polyol polymer having a greater number of hydroxy groups, an aliphatic acid ester of a polyol polymer having a greater number of hydroxy groups, and an aliphatic ether of a polyol polymer having a greater number of hydroxy groups are provided. A polymer obtained by polymerizing a polyol containing meso-erythritol, and an aliphatic acid ester and an aliphatic ether of the polymer are provided.

Abstract: Disclosed are compounds of the formula: 1